Şirket yükleniyor
Just reported
Q3 2026 results
From Puma Biotechnology's results release of 5 Kasım 2026; its quarterly report has since been filed.
Revenue
Actual
$55,1M
+%1,1 y/y
-%2,6 q/qGuided
$57,5M
midpoint
Below guide-%4,3EPS, GAAP
Actual
$0,11
-%35 y/y
-%31 q/qGuided
—
No guide given
Operating income, GAAP
Actual
$5,3M
-%45 y/y
-%30 q/qGuided
—
No guide given
Company outlook
Full year 2026
- Revenue$224M – $227M-%1,3 y/y First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Puma Biotechnology is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47,6BA+
EXELExelixis, Inc.$16,8BA+
JAZZJazz Pharmaceuticals plc$15,5BA
TECHBIO-Techne Corp$11,4BA+
HALOHalozyme Therapeutics, Inc.$11,4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 Eki 2026CBGraded C, now B
MCKMckesson Corporation4 Kas 2026BAGraded B, now A
CVSCVS Health Corp4 Kas 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 Kas 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 Eki 2026CAGraded C, now A
Puma Biotechnology, Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.
